News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of Aldafermin Administered for 24 Weeks for the Treatment of Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Study Status:

Study closed

Contact Information:

(956) 362-8047

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objectives are to evaluate the efficacy, safety, and tolerability of aldafermin based on liver histology at 24 weeks versus placebo


Principal Investigator
Jose Luis Almeda, MD
Guillermo Duran
NGM Biopharmaceuticals, Inc.
Type of Trial
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram